1. New York City Department of Health and Mental Hygiene. Unintentional Drug Poisoning (Overdose) Deaths in New York City in 2019. Epi Data Br [Internet]. 2020;122. Available from: http://www1.nyc.gov/assets/doh/downloads/pdf/epi/datatable66.pdf
2. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev [Internet]. 2014 Feb 6 [cited 2019 Nov 7]; Available from: http://doi.wiley.com/10.1002/14651858.CD002207.pub4
3. Edelman EJ, Chantarat T, Caffrey S, Chaudhry A, O’Connor PG, Weiss L, et al. The impact of buprenorphine/naloxone treatment on HIV risk behaviors among HIV-infected, opioid-dependent patients. Drug Alcohol Depend. 2014;139:79–85.
4. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ [Internet]. 2017 Apr 26 [cited 2019 Jun 4];j1550. Available from: http://www.bmj.com/lookup/doi/10.1136/bmj.j1550
5. Gryczynski J, Mitchell SG, Jaffe JH, O’Grady KE, Olsen YK, Schwartz RP. Leaving buprenorphine treatment: Patients’ reasons for cessation of care. J Subst Abuse Treat. 2014 Mar;46(3):356–61.
6. Jakubowski A, Fox A. Defining Low-threshold Buprenorphine Treatment. J Addict Med [Internet]. 2019 Sep [cited 2020 Apr 26];1. Available from: http://journals.lww.com/10.1097/ADM.0000000000000555
7. National Harm Reduction Coalition. Principles of Harm Reduction [Internet]. 2020 [cited 2021 Apr 6]. Available from: https://harmreduction.org/about-us/principles-of-harm-reduction/
8. Kapadia SN, Griffin JL, Waldman J, Ziebarth NR, Schackman BR, Behrends CN. A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study. J Gen Intern Med. 2021;
9. Pizzicato LN, Johnson CC, Viner KM. Correlates of experiencing and witnessing non-fatal opioid overdoses among individuals accessing harm reduction services in Philadelphia, Pennsylvania. Subst Abus [Internet]. 2020 [cited 2019 Nov 7];41(3):301–6. Available from: https://www.tandfonline.com/action/journalInformation?journalCode=wsub20
10. Van Boekel LC, Brouwers EPM, Van Weeghel J, Garretsen HFL. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: Systematic review [Internet]. Vol. 131, Drug and Alcohol Dependence. Elsevier; 2013 [cited 2019 Jun 25]. p. 23–35. Available from: https://www-sciencedirect-com.elibrary.einstein.yu.edu/science/article/pii/S0376871613000677
11. Bachhuber MA, Thompson C, Prybylowski A, Benitez J, Mazzella S, Barclay D. Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Subst Abus [Internet]. 2018 Apr 3 [cited 2019 Aug 4];39(2):167–72. Available from: https://www.tandfonline.com/doi/full/10.1080/08897077.2018.1443541
12. Carter J, Zevin B, Lum PJ. Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addict Sci Clin Pract [Internet]. 2019 May 6 [cited 2019 Sep 25];14(1):20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31060600
13. Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington. Subst Abus [Internet]. 2019 Aug 12 [cited 2019 Sep 8];1–9. Available from: https://www.tandfonline.com/doi/full/10.1080/08897077.2019.1635557
14. Stancliff S, Joseph H, Fong C, Furst T, Comer SD, Roux P. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis [Internet]. 2012 [cited 2018 Jul 25];31(3):278–87. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22873189
15. Hill K, Nussdorf L, Mount JD, Silk R, Gross C, Sternberg D, et al. Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment. J Addict Med. 2021;Publish Ah(00):1–8.
16. Cunningham CO, Giovanniello A, Li X, Kunins H V., Roose RJ, Sohler NL. A comparison of buprenorphine induction strategies: Patient-centered home-based inductions versus standard-of-care office-based inductions. J Subst Abuse Treat. 2011 Jun;40(4):349–56.
17. Health Resources and Service Administration. 340B Drug Pricing Program | Official web site of the U.S. Health Resources Services Administration [Internet]. HRSA. 2021 [cited 2021 Apr 12]. Available from: https://www.hrsa.gov/opa/index.html
18. Weiss L, Netherland J, Egan JE, Flanigan TP, Fiellin DA, Finkelstein R, et al. Integration of buprenorphine/naloxone treatment into HIV clinical care: Lessons from the BHIVES collaborative. J Acquir Immune Defic Syndr. 2011;56(SUPPL. 1):68–75.
19. Korthuis PT, McCarty D, Weimer M, Bougatsos C, Blazina I, Zakher B, et al. Primary Care-Based Models for the Treatment of Opioid Use Disorder: A Scoping Review. Ann Intern Med [Internet]. 2017 Feb 21 [cited 2019 Jan 21];166(4):268–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27919103
20. Hood JE, Banta-Green CJ, Duchin JS, Breuner J, Dell W, Finegood B, et al. Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington. Subst Abus [Internet]. 2020;41(3):356–64. Available from: https://doi.org/10.1080/08897077.2019.1635557
21. Fine DR, Lewis E, Weinstock K, Wright J, Gaeta JM, Baggett TP. Office-Based Addiction Treatment Retention and Mortality Among People Experiencing Homelessness. 2021;4(3).
22. Heller D, McCoy K, Cunningham C. An invisible barrier to integrating HIV primary care with harm reduction services: Philosophical clashes between the harm reduction and medical models. Vol. 119, Public Health Reports. 2004. p. 32–9.
23. Epstein RM, Street RL. The values and value of patient-centered care. Ann Fam Med. 2011;9(2):100–3.
24. Center for Drug Evaluation and Research. Drug Safety and Availability - FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. FDA.gov. 2017;2:1–6.
25. Chauhan BF, Jeyaraman M, Mann AS, Lys J, Skidmore B, Sibley KM, et al. Behavior change interventions and policies influencing primary healthcare professionals’ practice-an overview of reviews. Implement Sci [Internet]. 2017;12(1). Available from: http://dx.doi.org/10.1186/s13012-016-0538-8
26. Murphy SM, Jeng PJ, Poole SA, Jalali A, Vocci FJ, Gordon MS, et al. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): Protocol for an evaluation of two randomized effectiveness trials. Addict Sci Clin Pract [Internet]. 2020 Apr 22 [cited 2020 Sep 10];15(1). Available from: /pmc/articles/PMC7178627/?report=abstract